Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

1694-Melanoma metastatic ipilimumab and nivolumab (induction)

Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies - Kelsey Baron, Justin C Moser, Shiven Patel, Kenneth F Grossmann

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada, BMC Cancer

Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma - The ASCO Post

Nivolumab (Opdivo) Drug Information

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Metastatic Melanoma Therapies OPDIVO® (nivolumab) + YERVOY® (ipilimumab)

Full article: Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients

Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma